Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Looks To Enter Cancer Vaccine Field With TroVax Acquisition

Executive Summary

A collaboration between Sanofi-Aventis and Oxford BioMedica in the area of therapeutic cancer vaccines could extend beyond the development of TroVax to second-generation therapeutic vaccines combining technology from both companies, Sanofi Senior VP-Head of Oncology Allain Herrera said

You may also be interested in...



Provenge Approval Would Include Surveillance For Cerebrovascular Events

A pharmacovigilence study involving roughly 3,000 patients would be conducted by Dendreon to monitor safety events associated with Provenge, if FDA approves the therapeutic cancer vaccine

Dendreon’s Provenge Cancer Vaccine Shows “Substantial Efficacy” – Cmte.

Although not convinced that existing data fully prove the efficacy of Dendreon's Provenge, a majority of FDA's Cellular, Tissue and Gene Therapies Advisory Committee agreed during a March 29 meeting that there is "substantial evidence" the biologic is effective and should be approved

Oncophage Effect In Subgroup Supports Continued Development, Firm Says

Antigenics is seeing salvation for its Oncophage cancer vaccine based on signs of a clinically significant improvement in a subgroup of patients with a better prognosis in its Phase III renal cell carcinoma trial

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel